Elpis Biopharmaceuticals Pte Ltd.

Clearbridge Health Limited (Catalist:1H3) signed a binding term sheet to acquire Elpis Biopharmaceuticals, Pte. Ltd. from Chen Yan and Lim Chee Yong for $330 million on April 28, 2025. The transaction is subject to approval of offer by acquirer shareholders, approval of offer by acquirer board, consummation of due diligence investigation, definitive agreement and listing / approval of new shares on stock exchange, the completion of the reorganization of the Elpis Biopharmaceuticals, Pte. Ltd., obtaining financing of $3.05 million for acquisition of Elpis Biopharmaceuticals, Pte. Ltd.. UOB Kay Hian Pte Ltd acted as financial advisor for Clearbridge Health Limited.

Clearbridge Health Ltd. ( (SG:1H3) ) has shared an update. Clearbridge Health Limited has announced its entry into a binding term sheet for the proposed acquisition of Elpis Biopharmaceuticals Pte. Ltd. This acquisition, if completed, will result in a reverse takeover of Clearbridge Health, subject to shareholder approval and due diligence. The deal is expected to enhance Clearbridge Health’s market positioning by integrating Elpis Biopharmaceuticals’ capabilities, potentially impacting stakeholders by expanding the company’s operational scope and market reach. More about Clearbridge Health Ltd. Clearbridge Health Limited is a healthcare company based in Singapore, focusing on providing medical services and healthcare solutions across Asia. The company operates through various subsidiaries, offering a range of healthcare services including diagnostics, precision medicine, and healthcare systems. Technical Sentiment Signal: Buy Current Market Cap: €4.36M Find detailed analytics on 1H3 stock on TipRanks’ Stock Analysis page.

Clearbridge Health Limited (Catalist:1H3) signed a binding term sheet to acquire Elpis Biopharmaceuticals, Pte. Ltd. from Chen Yan and Lim Chee Yong for $330 million on April 28, 2025. The transaction is subject to approval of offer by acquirer shareholders, approval of offer by acquirer board, consummation of due diligence investigation, definitive agreement and listing / approval of new shares on stock exchange, the completion of the reorganization of the Elpis Biopharmaceuticals, Pte. Ltd., obtaining financing of $3.05 million for acquisition of Elpis Biopharmaceuticals, Pte. Ltd.. UOB Kay Hian Pte Ltd acted as financial advisor for Clearbridge Health Limited.